Thu. 13 Jun 2024, 10:46am ET
Benzinga
Biotech, News, General
- Kaplan-Meier Estimate of Duration of Response at 12 Months in Patients Who Achieved a Complete Response at Three Months was 82.3% (95% CI, 75.9%, 87.1%)
- Side Effect Profile Consistent with Previous Clinical Trials of UGN-102
- UroGen will Host a Virtual Event Today at 11:00 AM Eastern Time